Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in Patients With Stable Cardiovascular Disease (INTENSITY-HIGH)

Next Previous
Trial Profile

INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in Patients With Stable Cardiovascular Disease (INTENSITY-HIGH)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alirocumab (Primary) ; Atorvastatin; Ezetimibe; Rosuvastatin; Simvastatin
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms INTENSITY-HIGH

    • Most Recent Events

    • 22 Jul 2021 Planned End Date changed from 30 Nov 2020 to 30 Nov 2023.
    • 17 May 2021 Results assessing non-LDL effects of PCSK9i in stable CV disease patients who were otherwise ineligible for PCSK9i treatment, presented at the 70th Annual Scientific Session of the American College of Cardiology.
    • 07 Jan 2020 Planned End Date changed from 8 May 2019 to 30 Nov 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top